Bexson Biomedical raises $4.8m to advance wearable ketamine treatment for pain and mental health disorders

Bexson Biomedical has successfully raised $4.8 million in Series A funding to accelerate the development of its subcutaneous ketamine treatment platform, aimed at revolutionizing pain management and mental health care. This significant investment will help Bexson Biomedical scale its pre-clinical and Good Manufacturing Practice (GMP) operations for its novel ketamine formulation, BB106, while advancing the creation of a wearable ketamine delivery device in partnership with Stevanato Group, a leading medical device manufacturer.

The Series A round was led by Noetic Psychedelic Fund, which expressed confidence in Bexson Biomedical’s potential. Michael Franks, Managing Partner at Noetic Psychedelic Fund, remarked that he was excited to support Bexson Biomedical due to its innovative delivery technology, which operates within a vast global market. He highlighted that the company’s approach offers both a comprehensive solution set and a substantial commercial opportunity in the rapidly evolving field of psychedelic therapies.

How Bexson Biomedical plans to change pain management with ketamine

California-based Bexson Biomedical is currently in the research stage and focuses on creating a new method for delivering ketamine that could serve as a non-opioid alternative for pain management and mental health treatment. With the funds raised, the company plans to scale up the production of its ketamine formulation and continue its partnership with Stevanato Group to develop a wearable, programmable delivery device that facilitates dynamic and convenient subcutaneous delivery.

In September, Bexson Biomedical and Stevanato Group signed an agreement to manufacture a customized version of the SG EZ-be Pod. This small, wearable device is designed to offer a more user-friendly and cost-effective solution for ketamine delivery, addressing the limitations of existing infusion therapies that are often costly and cumbersome.

Bexson Biomedical’s wearable ketamine pump promises to reduce the procedural burden of traditional treatments, potentially increasing accessibility for patients who may benefit from ketamine’s therapeutic properties. Ketamine, traditionally used as an anesthetic, has shown promise in treating conditions like chronic pain, depression, and other mental health disorders, making it a valuable tool in the fight against the opioid epidemic.

Expanding the vision for non-opioid pain management

Beyond ketamine, Bexson Biomedical aims to develop new compounds targeting the NMDA receptor, similar to ketamine, for use in both pain management and central nervous system (CNS) disorders. The company is positioning itself to play a significant role in the future of pain management by offering alternatives to opioids—an area of increasing interest as the world grapples with the opioid crisis.

Gregg Peterson, co-founder and CEO of Bexson Biomedical, underscored the social and medical significance of their work. He pointed out that investor support reflects the valuable market opportunity Bexson’s innovations represent, particularly in the context of the opioid epidemic, which claims tens of thousands of lives annually. Peterson emphasized that a viable, FDA-approved alternative to opioid-based pain medications could provide significant social benefits, not only by reducing addiction rates but also by lessening the broader economic impact of the crisis.

The future of pain management and mental health treatment

Bexson Biomedical’s efforts are part of a larger trend of growing interest in psychedelic treatments for pain and mental health disorders. As the opioid crisis continues to claim lives and drain resources, Bexson’s innovations could provide much-needed alternatives for patients, offering both medical and societal benefits. By advancing the development of wearable ketamine delivery systems and pursuing other novel therapeutic options, Bexson Biomedical could be poised to make a lasting impact in the healthcare sector.

With its Series A funding, Bexson Biomedical is one step closer to bringing its innovative solutions to market. The company’s research could set a new standard for the treatment of chronic pain and mental health disorders, offering hope to millions of patients seeking alternatives to traditional therapies.